Active Ingredient History
Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis (Phase 3)
Arthritis, Juvenile (Phase 3)
Arthritis, Psoriatic (Phase 4)
Axial Spondyloarthritis (Phase 4)
Biliary Tract Neoplasms (Phase 1/Phase 2)
Colitis, Ulcerative (Phase 2)
Cystitis, Interstitial (Phase 3)
Drug Combinations (Phase 4)
Fibrosis (Phase 3)
Healthy Volunteers (Phase 1)
Hypertension (Phase 4)
Infertility, Male (Phase 1)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Melanoma (Phase 1)
Methotrexate (Phase 4)
Non-Radiographic Axial Spondyloarthritis (Phase 3)
Pregnancy Complications (Phase 2)
Pregnancy, High-Risk (Phase 2)
Psoriasis (Phase 3)
Sarcoma (Early Phase 1)
Spondylarthropathies (Phase 3)
Substance Withdrawal Syndrome (Phase 3)
Uveitis (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
